CTRI/2015/12/006473Other2 期
SAFETY AND EFFICACY OF BRIMONIDINE TARTRATE OPHTHALMIC SUSPENSION 0.35%ONCEDAILY AND ALPHAGAN® P 0.1%THRICE DAILY IN PATIENTS WITH OPEN ANGLE GLAUCOMA OROCULAR HYPERTENSION: A RANDOMIZED, OPEN LABEL, PARALLEL GROUP, ACTIVECONTROLLED STUDY
试验速览
- 阶段
- 2 期
- 状态
- Other
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Willing and able to give written informed consent.
- •-diagnosis of OHG or OAG
- •-Unmedicated IOP >= 22 mmHg and <= 36 mm Hg in one or
- •-Women of child bearing potential practicing an acceptable method of birth control
排除标准
- •-Women who are Pregnant nursing or planning a pregnancy or who were of childbearing potential and not using reliable method of contraception
- •-Known lack of ocular hypotensive response to topical ophthalmic alpha adrenergic receptor agonists in the opinion of the Investigator
- •-Severe or serious hypersensitivity to alpha-adrenergic agonist drugs
- •-Intraocular conventional surgery in any eye within the past six months
研究者
相似试验
已完成
2 期
Effect of Brimonidine on rosacea diseaseIRCT20161207031288N4Jarfandishan-e Navid-e Salamat (Janus) knowledge-based Company20
进行中（未招募）
1 期
Patient feedback of persistent facial rednessErythema of rosaceaMedDRA version: 20.0 Level: PT Classification code 10039218 Term: Rosacea System Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-005686-12-GBGalderma R&D80
进行中（未招募）
不适用
Patient feedback on the treatment of their persistent facial rednessEUCTR2012-005686-12-SEGalderma R&D80
进行中（未招募）
不适用
Patient feedback on the treatment of their persistent facial rednessEUCTR2012-005686-12-DEGalderma R&D80
已完成
2 期
Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric SubjectsOcular RednessNCT01675609Eye Therapies, LLC57